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Abstract Attention-deficit/hyperactivity disorder
(ADHD) is a highly prevalent psychiatric disorder in chil-
dren/adolescents. This study reviews available European-
based studies of ADHD-related costs and applies the find-
ings to the Netherlands to estimate annual national costs for
children/adolescents from a societal perspective. A sys-
tematic literature search was conducted for primary studies
in Europe, published January 1, 1990 through April 23,
2013. Per-person cost estimates were converted to 2012
Euros and used to estimate annual national ADHD-related
costs based on the Dutch 2011 census, ADHD prevalence
rates, family composition, and employment rates. Seven
studies met the inclusion criteria. The average total ADHD-
related costs ranged from €9,860 to €14,483 per patient and
annual national costs were between €1,041 and €1,529
million (M). The largest cost category was education
(€648 M), representing 62 and 42 % of the low- and high-
value overall national estimates, respectively. By
comparison, ADHD patient healthcare costs ranged
between €84 M (8 %) and €377 M (25 %), and social ser-
vices costs were €4.3 M (0.3–0.4 %). While the majority of
the costs were incurred by ADHD patients themselves,
€161 M (11–15 %) was healthcare costs to family members
that were attributable to having an ADHD child/adolescent.
In addition, productivity losses of family members were
€143–€339 M (14–22 %). Despite uncertainties because of
the small number of studies identified and the wide range in
the national cost estimates, our results suggest that ADHD
imposes a significant economic burden on multiple public
sectors in Europe. The limited number of European-based
studies examining the economic burden of ADHD high-
lights the need for more research in this area.
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Introduction
The burden of psychiatric disorders in developed countries
is large, representing up to 40 % of all brain diseases
(mental and neurological disorders) and 14 % of all dis-
eases [38]. A recent analysis has reported that the total cost
of psychiatric disorders in Europe was approximately €432
billion, of which direct healthcare costs, direct non-medical
costs and indirect costs represent 36, 12, and 52 %,
respectively, of the total [37]. This figure was higher than
previously estimated [2], but may still be a conservative
estimate given that not all costs were included because of a
lack of data on many disorders or cost items [37]. Costs of
attention-deficit/hyperactivity disorder (ADHD) in children
and adolescents were included in the analysis [37], but the
authors only assessed direct healthcare costs and direct
non-medical costs. Moreover, total costs were estimated
for Europe (represented by all members of the European
Union plus Iceland, Norway, and Switzerland). Thus, the
reported costs of ADHD did not capture the broad societal
impact of the disease, particularly at the national level,
which may be important in country-specific policy
decisions.
ADHD is a chronic behavioural disorder with onset in
childhood that often persists into adulthood [29, 46]. It is
characterized by symptoms of inattention, hyperactivity,
and impulsivity [1, 61]. Furthermore, the symptoms can
cause significant distress and impairment, and are perva-
sive (i.e., impairment is observed in many areas of life,
such as school performance, social function, and occupa-
tional achievement). The two main international diagnostic
criteria used clinically are the International Classification
of Diseases, 10th Edition (ICD-10) [61] and the Diagnostic
and Statistical Manual of Mental Disorders (DSM), 5th
Edition, Text Revision [1]. The former is predominately
used by European clinicians, while the latter is widely used
in the United States (US), as well as by some European
physicians [21]. The prevalence rates of ADHD in children
and adolescents are high with estimates of 5.3 % [45] to
5.9 % [59] worldwide and 4.6 % for Europe [45]. Similar
prevalence rates of approximately 5 % were observed for
adults with ADHD worldwide [59].
Impairments associated with ADHD are multi-faceted,
with outcomes such as academic failure, self-esteem
problems, and interpersonal relationship difficulties [11,
57, 60]. People with ADHD are also more prone to injuries
and accidents, including serious injuries and traffic acci-
dents, than those without ADHD [18, 31, 51]. Other
associations with ADHD include substance abuse problems
and interactions with the criminal justice system [32, 48,
52]. Not surprisingly, ADHD is associated with a reduction
in overall and health-related quality of life [7, 25]. More-
over, the negative impact of ADHD may extend to family
members, causing increased levels of stress, depression,
marital discord, and reduced health-related quality of life
for the family members of patients with ADHD [30, 33,
34]. While these long-term outcomes are worse for people
with ADHD compared to those without, treatment using
pharmacological, non-pharmacological, or combined
approaches (e.g., medication and behavioural therapy) can
ameliorate some of the negative impacts of the disorder
[44, 50]. Treatment of ADHD may also have benefits
beyond the individual. Comparing ADHD medication use
and incidences of criminality among patients with ADHD,
Lichtenstein et al. [28] have reported that the rates of
criminality were lower during periods of medication use
compared to periods off medication in the same patients.
Children and adolescents with ADHD consume more
healthcare resources and consequently incur more health-
care costs compared to those without ADHD [15, 27, 47].
The financial impact of ADHD, however, affects many
facets of a child’s life. A recent analysis of the economic
burden of ADHD in the US highlighted that the majority of
total disorder costs lie outside the healthcare sector, and
because ADHD often persists into adulthood, costs of
ADHD in the adult population are also substantial [10].
Furthermore, the financial burden of ADHD is not
restricted to patients alone. Family members also incur
significant costs, in the form of increased healthcare costs
and productivity loss [4, 10, 54].
Similar cost-of-illness studies are scarce in Europe, and
there is a lack of understanding of the economic burden of
ADHD in Europe. The purpose of this study is to review
the available evidence and to apply the findings to quantify
the societal economic burden of ADHD in a European
setting, using the Netherlands as a reference case. The
focus of the present study is on the costs of ADHD in
children and adolescents because there were no studies on
adult ADHD-related costs identified.
Methods
Systematic literature search
A systematic review was conducted using guidelines from
the Cochrane Handbook for Systematic Reviews of Inter-
ventions [17]. Five large databases (MEDLINE, EMBASE,
ERIC, HEED, and PsycINFO) were searched for articles
published from January 1, 1990 through April 23, 2013
using the following abstracted search strategy: (terms
describing ADHD) AND [(terms describing cost analysis
or economic impact) OR (terms describing areas of cost
due to ADHD)] (See Supplementary Table 1 for search
term details). Search dates were between June 1, 2011 and
April 23, 2013.
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The screening process is outlined in Fig. 1. Two
researchers reviewed the citations and abstracts indepen-
dently and agreed on the studies to be included. Any dis-
crepancies were resolved upon review of the full text by the
two reviewers and/or consultation with a third researcher.
Articles retained for analysis (any language) included all
those that were classified as original research studies of
human participants conducted in Europe that monetized
ADHD-related outcomes, either the excess costs of a
population with ADHD compared with those of non-
ADHD controls or costs specifically related to an ADHD
diagnosis. All studies were original research and peer-
reviewed; meta-analyses, case studies, editorials, opinion
papers, and review articles were excluded. Studies in which
costs related to ADHD were not analysed separately from
other disorders were excluded. Study characteristics and
cost measurements for included studies were extracted and
tabulated by two researchers independently (all discrep-
ancies were resolved between these two researchers), and
fact-checked by a third researcher.
Extraction and calculations of per-person ADHD-
related costs
Some calculations and/or adjustments of the data reported
in the studies were required to align the information pre-
sented in the papers to our framework. From the Wehmeier
et al. [58] study, the total cost of treatment for hyperkinetic
disorder in Germany for the age group \15 years was
reported to be €287 million in 2006. Per-patient annual
costs were computed by dividing the aggregate annual
national costs by an estimated ADHD population size for
this age group, which was derived using sex-specific
prevalence rates [22, 36] and the applicable population
size, matching as closely as possible the age distribution
and census year with the year of study [22, 36]. From these
calculations, the estimated ADHD population (aged
\15 years) was 406,787, giving an estimated per-person
cost of €706. After adjustments to Dutch 2012 euros, this
figure becomes €856, which is comparable to the inflated
estimate of €798 from Scho¨ffski et al. (another German
study on the healthcare cost of ADHD) [35, 49, 55, 58]. In
the Myren et al. [35] study, direct and indirect costs at
baseline were reported for the treatment and placebo
groups 10 weeks prior to an ADHD treatment period. As
these baseline values represented costs before initiation of
ADHD treatment, the data from both groups were com-
bined. For this study, the productivity loss component of
the combined indirect costs was extracted from data gained
through written communication with the corresponding
author. All 10-week costs were then extrapolated to annual
costs.
All cost estimates reported in foreign currencies were
converted to Euros for the matching year using gross
6,202 total
search yield
Primary review of title, type of
article, and remaining duplicates
(4,637 excluded)
Secondary review of abstract for
cost analysis and ADHD study group
(1,461 excluded)
Full text review for full inclusion
criteria, participants ages, 
and country of origin
(97 excluded)






Fig. 1 Flow chart describing
the systematic literature review
process. ADHD attention-
deficit/hyperactivity disorder
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domestic product per capita purchasing power parity pro-
vided by the Organisation for Economic Co-operation and
Development [40]. These estimates were then inflated to
2012 levels using the Harmonized Index of Consumer
Prices (HICP) for Education, Health, and Social Protection
for the Netherlands as provided by the Federal Reserve
Economic Data from the Federal Reserve Bank of St. Louis
[14].
Estimation of annual national ADHD-related costs
Costing data were drawn from all European studies meet-
ing our inclusion criteria. From the included studies, per-
patient cost estimates were used to calculate national
ADHD-related costs for the Netherlands, the European
reference country for this study. This study did not assess
or adjust for differential study quality or characteristics
beyond those specified in the inclusion criteria (original,
peer-reviewed research studies), including inherent statis-
tical limitations of studies with a small sample size. As a
result, point estimates for national costs were not calcu-
lated but instead the lowest and highest per-patient cost
categories for each subcategory were identified (when
more than one data source was available) and then used to
estimate a total national ADHD-related cost range.
The number of children and adolescents aged
7–17 years with ADHD in the Netherlands was estimated
by multiplying the 2011 Dutch census estimates for this
age group with the estimated prevalence of ADHD in the
Netherlands. The only published ADHD prevalence esti-
mate (2.1 %) for the Netherlands, however, is limited to
prevalence of pharmacologically treated children and
adolescents with ADHD [20]. Use of this ‘treated ADHD’
prevalence rate would likely result in an underestimate of
the national costs of ADHD in the Netherlands as undi-
agnosed and/or untreated children and adolescents with
ADHD would also incur healthcare- and education-related
costs. Hence, in our base-case analysis, we used a preva-
lence rate of 4.8 % reported for German children and
adolescents aged 7–17 years [22]. Data from the German
study were used as a proxy for the Netherlands because of
the social, economic, and cultural similarities between the
two countries. Moreover, the German prevalence rate was
similar to the reported ADHD prevalence for Europe
(4.6 %) [45]. In the sensitivity analysis (described later in
this section), we used the treated ADHD prevalence rate
(2.1 %) reported in the Netherlands.
The estimation of the number of family members
incurring costs related to ADHD required additional mul-
tiplication factors to determine the population size incur-
ring the costs. Because the costs of healthcare and
productivity losses to family members of patients with
ADHD were applicable to adult members and not to other
siblings of similar age in our analysis, a multiplication
factor representing the average number of adults in
households with children in the Netherlands was needed.
This adult member multiplication factor was estimated to
be 2.26 and was derived from the reports ‘SF1.1 Family
Size and Composition’ [41] and ‘SF1.4: Population by Age
of Children and Young Adults, and Youth-Dependency
Ratio’ [42] by the Organisation for Economic Co-Opera-
tions and Development (OECD). The percentages of cou-
ple families and single-parent families of all households in
the Netherlands were combined with the average house-
hold sizes of couples with children and single-parents with
children to derive the average size of Dutch households
with children [41]. The proportion of adults in these
households was calculated using the youth-dependency
ratio [42]. This factor was used to calculate healthcare
costs to adult members living in households with a child/
adolescent with ADHD. The product of the employment
rate in the Netherlands for 2011 (0.77) and the adult
member multiplication factor (2.26) was used to determine
the number of family members whose work productivity
would be affected by a child/adolescent with ADHD [12,
41, 42].
For each cost category, the low and high per-patient cost
estimates were used to establish an annual national cost
range for that category. For some categories such as
healthcare costs to family members or education and social
services costs to patients with ADHD, however, only one
estimate was available. In these cases, the same estimate
was used to calculate the low and high values in the range
of total national costs. While there were two studies that
investigated costs of education for patients with ADHD,
these studies reported different aspects of education costs
[8, 55]. De Ridder and De Graeve [8] included only the
costs to the parents from extra school lessons for their
child/adolescent with ADHD, whereas Telford et al. [55]
examined various elements of costs to the education system
such as services and time commitment from teachers,
social workers, counsellors, educational psychologists, etc.
but did not include extra school costs to the parents [55].
Thus, the sum of the two estimates was used to establish
one overall per-patient education cost.
Sensitivity analysis
The methods described above are for the base-case ana-
lysis. In economic modelling, the base-case represents the
most likely assumptions on model structure and/or input
parameters/data. Sensitivity analyses are also recom-
mended to evaluate the robustness of the results as well as
to assess different relevant scenarios. Thus, in addition to
the base-case analysis, three sensitivity analyses were
performed to vary key parameters in our base-case
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analysis. In the first scenario, the ADHD prevalence rate
(4.8 %) was changed to the diagnosed and treated preva-
lence rate (2.1 %) for the Netherlands [20].
The second scenario included a study by Petrou et al. [43],
which did not meet the inclusion criteria for the base-case
analysis because it reported an aggregated estimate for
healthcare, education, and social services. The Petrou study is
similar to the Telford study [55] in that both studies estimated
costs of ADHD in the UK and the same cost categories were
investigated, albeit an aggregated estimate was reported in
the former whereas disaggregated estimates were provided in
the latter. From these similarities, we assumed that the
merged estimate from the Petrou study could be disaggre-
gated into each cost category according to the distribution
profile that was observed in the Telford study. As a result of
the disaggregation, new per-person low estimates for
healthcare, education, and social services costs to the patients
with ADHD were used in the national cost calculation.
The last scenario included a study by Knapp et al. [26]
that investigated the connections between attention deficit
problems in childhood and future earnings in adulthood.
The authors used the 1970 British Cohort Study to collect
data on attention deficit problems at age 10 years (assessed
by the Connors Teachers Rating Scale) and employment
activities at age 30 years. A probit regression model was
used to assess the influence of childhood variables on future
employment and occupational status. Combining the result
of the probit model with an analysis on earnings of those in
employment, the authors calculated the impact of attention
deficit problems in childhood on expected earnings in
adulthood. The findings from this study suggested that
attention deficit problems at age 10 years were associated
with lower employment rates, worse jobs, and lower wages
when employed, leading to overall lower expected earnings
at age 30 years. The authors reported £36 and £61 in weekly
income losses for males and females, respectively. Annual
income losses were calculated using an estimated average
of working weeks per year in the Netherlands (45.2 weeks)
[39]. Based on the applicable population sizes of males and
females, a weighted average for annual income losses was
estimated to be €4,486 after currency conversion and
inflation to 2012 level. In the sensitivity analysis, we
included this future income loss as an additional cost cat-
egory for children and adolescents with ADHD.
Results
From an initial yield of 6,202 citations, a primary review of
the titles, type of articles, and remaining duplicates exclu-
ded 4,637 studies (Fig. 1). Upon a review of each study
abstract to identify the ADHD study population and cost
analysis, another 1,461 studies were excluded, leaving 104
potential studies. After a full-text review, seven studies on
cost of ADHD in children and adolescents met full inclu-
sion criteria for base-case analysis [5, 8, 16, 35, 49, 55, 58]
and two studies were retained for sensitivity analysis [26,
43]. Study characteristics of those used in the base-case
analysis are summarized in Table 1. The included studies
were from five northern/western countries from the Euro-
pean Union (EU): Belgium, Germany, the Netherlands,
Sweden, and the United Kingdom. Most studies were ret-
rospective analyses with the exception of one prospective
analysis [16] and one placebo-controlled clinical trial [35].
ADHD was diagnosed according to either ICD-10 or DSM
4th edition. Text revision criteria in all studies but one
where the Connors Teacher Rating Scale was used [8]. Four
studies used the total cost approach [35, 49, 55, 58] while
three studies used the incremental cost approach [5, 8, 16]
to identify ADHD-related costs. Last, most studies did not
provide adjustment for possible confounders.
Five cost categories, for which costing data were avail-
able, were identified. Three categories were costs attribut-
able to the child/adolescent with ADHD themselves
(healthcare, education, and social services) and two were
costs to family members that were due to ADHD-related
activities of a child/adolescent with ADHD (healthcare costs
and productivity loss). A list of the cost components that
were described in each of the studies is provided in Sup-
plementary Table 2. A summary of per-patient and per-
family member cost estimates for each study is presented in
Table 2. All studies reported ADHD-related healthcare costs
attributable to patients. The estimates were between €798
and €3,571. One study also measured healthcare costs to
family members (€675) [16]. Two studies reported costs for
education [8, 55] and produced a derived estimate of €6,085.
One study also considered social services costs utilized by
the patient (€40) [55]. Productivity loss to family members of
patients with ADHD was estimated in two studies to be
between €781 [35] and €1,845 [16] per family member.
Base-case analysis
The low and high estimates from each cost category were
used to derive a range for total annual national ADHD-
related costs for the Netherlands (Table 3). Annual national
ADHD-related healthcare costs for children/adolescents
with ADHD ranged between €84 and €377 million, and
ADHD-related healthcare costs by family members were
€161 million (Table 3). ADHD-related education and
social services costs were €648 and €4.3 million, respec-
tively. Productivity loss by family members due to ADHD-
related activities of the child/adolescent was estimated to
range from €143 to €339 million. Summing the estimates
across the categories gave a range for the total national
annual ADHD-related costs of €1,041–€1,529 million.
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Total annual per-patient costs were calculated from the
total annual national costs because the applicable popula-
tion is not the same across the different cost categories.
National costs to family members were divided by the
ADHD patient population to estimate the costs to family
members per ADHD patient instead of costs per family
member as reported in the included studies. For example,
annual ADHD-related costs of healthcare for the patients
and the family members ranged from €2,322 to €5,095 per
ADHD patient (Table 3). Productivity loss by family
Table 2 Annual per-person ADHD-related costs by categories, adjusted to 2012 Dutch Euros
Study Annual per-person costs (2012 Dutch Euros)a
Child/adolescent ADHD patient Family member
Healthcare Education Social services Healthcare Productivity loss
De Ridder and De Graeve [8] €1,436 €56
Hakkaart-van Roijen et al. [16] €2,191 €675 €1,845
Scho¨ffski et al. [49] €798
Wehmeier et al. [58] €856
Myren et al. [35] €2,009 €781
Telford et al. [55] €1,918 €6,085 €40
Braun et al. [5] €3,571
ADHD attention-deficit/hyperactivity disorder
a These estimates were used to establish the low and high range for national cost estimates























ADHD patients 7 2,199,000 4.80 – 105,552 €798–€3571 €84–€377
Family members 1 2,199,000 4.80 2.26d 238,325 €675 €161
Subtotal per patiente €2,322–€5,095 €245–€538
Education costs
ADHD patients
Extra lessons 1 2,199,000 4.80 – 105,552 €56 €5.9
Education system 1 2,199,000 4.80 – 105,552 €6,085 €642
Subtotal per patiente €6,141 €648
Social services costs
ADHD patients 1 2,199,000 4.80 – 105,552 €40 €4.3
Subtotal per patiente €40 €4.3
Productivity and income losses
Productivity losses (family) 2 2,199,000 4.80 2.26d, 77 %f 183,511 €781–€1,845 €143–€339
Subtotal per patiente €1,358–€3,208 €143–€339
Total per patient €9,860–€14,483 €1,041–€1,529
ADHD attention-deficit/hyperactivity disorder
a The Dutch Census, 2011; Centraal Bureau voor de Statistiek
b Age range of population was 7–17 years
b Huss et al. [22]
d Average number of adults in Dutch households with children, rounded from 2.25789631487208
e Per-patient cost is not the sum of per patient (per patient and per family member) costs. It was calculated using the national costs and ADHD
patient population
f Employment rate for the Netherlands (20–64 years); European Commission Eurostat Labour Force Survey, 2011
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members ranged between €1,358 and €3,208 per patient.
Annual costs for education and social services per patient
were €6,141 and €40, respectively. This corresponded to an
average total annual cost per child/adolescent with ADHD
between €9,860 and €14,483.
While the majority of the total cost was attributable to
ADHD patients, costs to the family members accounted for
29–33 % of the total (Fig. 2). When considering the contri-
butions of the different categories to the total cost, healthcare
costs for ADHD patients were 8–25 % (Fig. 3). The most
costly category was education, accounting for 42–62 % of
the total. For family members, ADHD-related healthcare
costs (11–15 %) and ADHD-related productivity losses
(14–22 %) were comparable to healthcare costs for ADHD
patients. Costs of social services for children/adolescents
with ADHD constituted the smallest proportion (0.3–0.4 %).
Sensitivity analysis
When using the diagnosed and treated ADHD prevalence
rate for the Netherlands, the annual national cost range was
reduced to between €455 and €669 million (Table 4). The
inclusion of the disaggregated estimates from the Petrou
et al. [43] study produced new low estimates for healthcare
costs for the patient and costs to the education system and
social services. This resulted in a new low estimate for the
annual national cost of €372 million. A study that projected
occupational consequences of children with ADHD when
they become adults suggested that those diagnosed with
ADHD in their childhood lost on average €4,486 per year
in future earnings due to lower wages [26]. When including
this study in a sensitivity analysis, the annual national costs
of ADHD increased to between €1,514 and €2,002 million.
Discussion
To the authors’ knowledge, this is the first systematic
review and analysis of ADHD cost of illness studies in
Europe. Because of the small number of studies on cost of
ADHD across Europe, the findings from the systematic
review were pooled and then used to estimate the total












Fig. 2 National ADHD-related
costs (in millions) of ADHD
patients and family members.
The inner circle represents the
low range estimate (€1,041 M)
and the outer circle represents
the high range estimate



























Fig. 3 National attention-
deficit/hyperactivity disorder-
related costs (in millions) by
cost categories. The inner circle
represents the low range
estimate (€1,041 M) and the
outer circle represents the high
range estimate (€1,529 M)
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The results indicate that societal ADHD-related costs are
approximately €1 billion annually for a country with a
population of around 16 million. A similar study conducted
in the US by Doshi et al. [10] reported that the total annual
national cost of ADHD was estimated to be between $143
and $266 billion. There are several factors contributing to
the difference in the national estimates between the two
studies. First, the population size of the US is approximately
19-times larger than the Netherlands. Second, the reported
prevalence rate of ADHD in children and adolescents in the
US is higher than the prevalence rate used in this analysis
[22, 56]. Last, there were more cost-of-illness studies of
ADHD in the US compared with Europe. Thus, Doshi et al.
were able to identify more cost categories such as costs to
the justice system and more importantly costs of ADHD in
adult patients. Costs to adult patients were major contrib-
utors to overall costs, representing approximately 73 % of
the $143 and $266 billion estimates. These cost categories
were not available in the present analysis. Hence, our esti-
mates on only children/adolescents are limited in measuring
the true societal impact of ADHD to the nation.
An important finding of our analysis was that the
healthcare costs represented a small proportion (8–18 %)
of the overall national ADHD-related costs in the Nether-
lands. The observation that the majority of the ADHD-
related costs was outside of the healthcare sector has
important policy-making implications given the social
insurance systems in Europe [10]. In European social
insurance systems, policy makers may find it beneficial to
invest in improving the diagnosis and management of
ADHD because this may offset costs in other sectors like
education and the justice system, as well as productivity
loss in the workforce. The economic impact of early
diagnosis and treatment of ADHD in Europe, however, has
not yet been investigated. This clearly warrants further
research. In addition, a more complete understanding of the
costs associated with ADHD in different public sectors
may aid in budget decisions across the different sectors.
While healthcare is not the major cost driver of ADHD,
it is the most investigated cost category. With the exception
of patient education and productivity loss to family mem-
bers, which were each included in two studies, the other
cost categories were investigated by just a single study.
The scarce evidence on ADHD-related costs other than
healthcare highlights the need for more cost research in
education, social services, and the financial impact of
productivity loss by family members of children and ado-
lescents with ADHD. This literature review also identified
costs to the justice system, substance abuse treatment, and
traffic accidents as areas that have been suggested to be
negatively impacted by ADHD but for which no cost-of-
illness studies are presently available in Europe. Further-
more, there is a complete lack of studies investigating cost
of ADHD in adult patients in Europe, even though this cost
category may represent the majority of the total cost, as in
the US [10].
Limitations and biases
The major limitation of the study was the small number of
studies that were included in the analysis. Moreover,
included studies did not report the same cost categories. As
a result, most cost categories, other than healthcare costs,
were reported by only one or two studies. This further
limited the available evidence on overall costs of ADHD,
which increased the uncertainties around the annual
national cost estimates. Given the limited data, a point
estimate for annual national cost was not provided, because
high variance between studies was expected. Instead, low
and high values for each cost category, when possible,
were used to estimate a range for the annual national cost.
Compounding of error was a concern also, especially
considering the small sample of studies and extrapolation
to large monetary values.
In addition to the small number of studies, there were
other potential sources of bias. For instance, the seven
included studies were from five different countries of the
EU. Only one study was based in the Netherlands; of the
remaining studies, three came from Germany and one each
from Belgium, Sweden, and the UK. While all of these
studies meeting the inclusion criteria were coincidentally
based in northern/western countries of Europe, which share
similar social-economic characteristics and cultural views
on the treatment of ADHD, applying between-country cost
estimates to the Netherlands may introduce bias given the
differences in the healthcare, education, and social support
systems across these countries. Whether this issue results in
under- or over-estimation of the true overall national costs
in the Netherlands is not clear.
Some insights may be gained by considering the con-
tribution of the cost estimates from the single study
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conducted in the Netherlands to the overall national cost
calculations [16]. The study by Hakkaart-van Roijen et al.
[16] reported estimates for healthcare costs of patient,
healthcare costs of family members, and productivity costs
of family members. These estimates were represented in
three of the five cost categories used to derive the high-
range national costs, but was only used in one (healthcare
costs of family members) of the five categories for the low-
range national costs. Considering the contributions of the
Dutch cost estimates to the overall national costs would
suggest that potential between-country bias is lower for the
high-range estimation and higher for the low-range esti-
mation. Using the same line of argument, the true cost of
ADHD in the Netherlands would more likely be closer to
the estimated high-range national costs.
Other sources of heterogeneity may have arisen from
differences in study designs, ranging from retrospective
analyses to a clinical trial setting (Table 1). Furthermore,
there were differences in ADHD diagnostic criteria used,
type of methodological approach, and whether or not the
estimates were adjusted for confounders. All these factors
contributed to the overall uncertainty of the cost estimates.
Potential factors for underestimation
and overestimation
The prevalence rate of ADHD in children and adolescents
in the Netherlands is not known. Consequently, a preva-
lence rate from Germany was used as a proxy, which has
face validity but the consequence of which is that the true
prevalence rate of ADHD in the Netherlands may be under-
or overestimated. Nevertheless, even if a prevalence rate of
2.1 % for diagnosed and treated Dutch ADHD patients was
used [20], as was done in the sensitivity analysis, the
annual national costs of ADHD were still approximately
€500 million. This estimate would likely be an underesti-
mation as the true prevalence rate would be higher than the
diagnosed and treated ADHD rate.
There are a number of other factors that suggest an
underestimation of ADHD-related costs. For example, not
all relevant cost categories were included, because of lack
of data. There were no studies reporting costs to the justice
system, substance abuse treatment, or traffic accidents. It is
reasonable to assume that ADHD would impose costs in
these areas [3, 32, 48, 52]. Underestimation may also occur
because not all cost components were included in each of
the cost categories.
Furthermore, the present study included only costs
related to ADHD in children and adolescents. When con-
sidering potential future income losses to children with
ADHD as adults in the work force, the annual national
costs of ADHD in children and adolescents increased to
approximately €1.5 billion. Costs of ADHD directly
attributable to adult patients, however, were not evaluated
because there were no European-based studies on the topic.
Nevertheless, it is known that ADHD persists into adult-
hood [24] and the prevalence rate of ADHD in adults is
comparable with the estimates for ADHD in children [9,
13, 59]. Thus, it is reasonable to assume that including
costs to adult patients would increase the total cost of
ADHD [6, 10, 19]. Moreover, the increase may be quite
large considering the findings by Doshi et al. [10] that cost
of ADHD in adults represented approximately 73 % of the
total national cost.
There were also factors that may have contributed to an
overestimation of the national cost estimates in the present
analysis. Most studies that were used in the analysis
reported cost estimates that were not adjusted for possible
confounders. For example, it is well established that
ADHD is commonly associated with comorbidities such as
depression, anxiety, bipolar mood disorder, and conduct
disorders [23, 53, 62]. Thus, cost estimates that do not
adjust for comorbidities may overestimate the ADHD-
specific costs.
In summary, the findings in this study offer a broad
estimation of the societal costs of ADHD. While
acknowledging the limitation of the analysis, the societal
economic impact of ADHD for the Netherlands remains
large. In addition, as the impairments associated with the
disorder are multi-faceted and occur in multiple settings,
societal costs associated with ADHD also impact multiple
public sectors in addition to healthcare, with the majority
of the costs lying outside of the healthcare sector.
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